소화기 진단 시장 : 검사 유형, 기술, 용도, 최종 용도별, 세계 예측

Global Gastrointestinal Diagnostics Market will witness 4.6a% CAGR between 2024 and 2032, driven by the surge in innovative device launches. Recent advancements in diagnostic technology are enhancing the accuracy, speed, and comfort of gastrointestinal assessments. New devices, such as advanced endoscopes, capsule endoscopes, and non-invasive imaging tools, offer improved visualization and diagnostic capabilities, enabling earlier and more precise detection of gastrointestinal conditions.

These innovations are crucial for managing complex disorders like colorectal cancer, Crohn's disease, and irritable bowel syndrome. For instance, in May 2024, Laborie Medical Technologies Corp., a leading company in diagnostic and therapeutic medical technology, launched the Solar Compact System and the Solar Anorectal Manometry Catheter, which first disposable HRAM catheter available.

The rise in innovative diagnostic tools is also fueled by increasing awareness of gastrointestinal health and the demand for personalized medicine. Enhanced diagnostic accuracy helps in tailoring treatment plans, improving patient outcomes, and reducing healthcare costs. As manufacturers continue to develop and introduce cutting-edge devices, the gastrointestinal diagnostics market is expected to expand further, driven by the need for advanced, efficient, and patient-friendly diagnostic solutions.

The overall Gastrointestinal Diagnostics Industry value is classified based on the test type, technology, application, end-use, and region.

Based on test type, the gastrointestinal diagnostics market revenue from the blood test segment will register a commendable CAGR from 2024 to 2032. Innovative blood-based diagnostic assays are offering non-invasive, accurate methods for detecting gastrointestinal disorders, such as colorectal cancer and inflammatory bowel disease. These tests utilize biomarkers and genetic indicators to provide early diagnosis and monitor disease progression. The convenience and reduced patient discomfort associated with blood tests drive their growing popularity. Additionally, the emphasis on preventive healthcare and early detection is fueling market expansion. As research continues to enhance the efficacy and range of blood tests, their role in gastrointestinal diagnostics is expected to further boost market demand.

In terms of technology, the ELISA segment will witness an appreciable growth from 2024 to 2032. ELISA offers a highly sensitive and specific method for detecting biomarkers related to various gastrointestinal conditions, including infections, inflammatory diseases, and cancers. Its ability to provide accurate quantitative results makes it invaluable in both clinical and research settings. The increasing prevalence of gastrointestinal disorders and the need for reliable diagnostic tools are driving the demand for ELISA-based tests. As technology advances and more biomarkers are identified, the role of ELISA in gastrointestinal diagnostics is expected to expand, further fueling market growth.

Europe gastrointestinal diagnostics market will exhibit a notable CAGR from 2024 to 2032. European healthcare providers are increasingly adopting advanced diagnostic tools, such as endoscopes, imaging devices, and biomarker tests, to enhance the accuracy and efficiency of gastrointestinal disease detection and management. The region's focus on early diagnosis and personalized medicine further fuels demand. Additionally, stringent regulatory standards and investments in research and development support the growth of innovative diagnostic solutions. As Europe continues to prioritize gastrointestinal health and advanced diagnostics, the market is expected to see continued robust growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of gastrointestinal diseases
    • 3.2.1.2 Growing adoption of non-invasive tests
    • 3.2.1.3 Rising awareness about gastrointestinal health
    • 3.2.1.4 Technological advancements in diagnostic technologies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of diagnostic procedures
    • 3.2.2.2 Limited reimbursement policies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Endoscopy
• 5.3 Blood test
• 5.4 Immunoglobulin A test
• 5.5 H. pylori test
• 5.6 Calprotectin test
• 5.7 Other test types

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Culture and sensitivity testing
• 6.3 ELISA
• 6.4 PCR
• 6.5 Imaging technologies
• 6.6 Rapid diagnostic tests
• 6.7 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Infection
• 7.3 Gastrointestinal cancer
• 7.4 Inflammatory bowel disease
• 7.5 Gastroesophageal reflux disease (GERD)
• 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Diagnostic laboratories
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 Beckman Coulter, Inc.
• 10.3 Becton, Dickinson and Company
• 10.4 bioMerieux
• 10.5 Bio-Rad Laboratories, Inc.
• 10.6 DiaSorin S.p.A
• 10.7 EKF Diagnostics Holdings plc
• 10.8 F. Hoffmann-La Roche Ltd
• 10.9 Fujifilm Holdings Corporation
• 10.10 Meridian Bioscience
• 10.11 QIAGEN N.V.
• 10.12 R-Biopharm AG
• 10.13 Siemens Healthineers AG
• 10.14 Sysmex Corporation
• 10.15 Thermo Fisher Scientific Inc.